High-dose chemotherapy and autologous stem cell rescue is considered a standard part of initial therapy for patients with multiple myeloma. Therefore, potential transplant candidates are generally treated with dexamethasonebased programs rather than alkylating agents to avoid stem cell toxicity. The optimal mobilizing regimen for patients with multiple myeloma has not been defined. However, aggressive chemotherapy may result in excessive morbidity and cost in this older, immunocompromised population. We retrospectively examined our experience with a well-tolerated regimen of 1.5 g/m 2 cyclophosphamide on day À10 followed by 10 lg/kg G-CSF beginning on day À7 in 50 consecutive patients with multiple myeloma and no prior alkylating agent therapy. Median stem cell collection was 4.88 Â 10 6 CD34 þ cells/kg per apheresis and 44 patients collected 45 Â 10 6 CD34 þ cells/kg within 2 days. In 36 patients, more than 10 Â 10 6 CD34 þ cells/kg were collected including 33 patients who required 1-2 days of collection. One patient required hospitalization for fever/neutropenia and two required weekend apheresis. We conclude that 1.5 g/m 2 cyclophosphamide plus 10 lg/kg G-CSF is a safe, effective, highly predictable mobilizing program that uniformly provided enough stem cells for one transplant and enough stem cells for two transplants.
mobilization; autologous
Consolidation with high-dose chemotherapy and autologous stem cell rescue has been shown to be superior to continued conventional chemotherapy for newly diagnosed patients with multiple myeloma. 1 A preliminary report has also suggested that a second or tandem transplant may lead to better event-free and overall survival than a single course of high-dose therapy. 2 The early use of high-dose therapy has resulted in a change of initial therapy for potential transplant candidates. Thus, dexamethasone-based programs such as pulse dexamethasone, vincristine/doxorubicin/dexamethasone (VAD) or, more recently, thalidomide/ dexamethasone, have increasingly replaced equally effective, well-tolerated alkylating agent-based programs because of the latter's deleterious effects on efforts to mobilize hematopoietic progenitor cells. [3] [4] [5] Owing to these changes in the treatment of multiple myeloma, stem cells are routinely collected after three to four cycles of non-stem cell toxic therapy. As a result, more aggressive mobilizing regimens such as the use of high-dose (4.0-7.0 g/m 2 ) cyclophosphamide may not be necessary to achieve adequate stem cell collections in patients currently referred for high-dose therapy. In addition, as more intensive mobilizing programs are more toxic, morbidity and cost are increased without any known benefit. 6,7 As 1.5 g/m 2 cyclophosphamide and 10 mg/kg/day G-CSF were previously shown to be effective in mobilizing stem cells in lymphoma patients, 8 we used the same program in 50 patients with newly diagnosed multiple myeloma. In addition to achieving adequate stem cell collections, we were also interested in the incidence of hospitalization caused by mobilizing therapy, the number of aphereses required and the ability to avoid off-hour (weekend) apheresis.
Patients and initial treatment
Our database for multiple myeloma included 80 patients who had stem cell mobilization between 1998 and 2001 in anticipation of autologous transplant. The 50 patients included in this study had not been previously treated with alkylating agents and were all mobilized with 1.5 g/m 2 cyclophosphamide plus G-CSF 10 mg/kg. Prior treatment included pulse steroids, VAD or a combination of the two; 11 patients also received radiation therapy to control symptomatic bony disease.
Mobilization of stem cells
As shown in Figure 1 , 1.5 g/m 2 cyclophosphamide was given at the referring physician's office on a Friday (day À10) as an outpatient 3-4 weeks after the final cycle of debulking therapy. Patients were given 500 ml of prehydration followed by 1.5 g/m 2 cyclophosphamide in 500 ml of normal saline over 2 h. An additional liter of posthydration was given. MESNA uroprophylaxis was not administered. Beginning on the following Monday (day À7), 10 mg/kg/ day G-CSF was given subcutaneously daily until stem cell collection was completed. Higher doses of G-CSF were allowed in the event of poor mobilization. Apheresis through peripheral veins or a short term, centrally placed Quinton catheter (Mahurkar, Quinton Instrument Company, Bothwell, WA, USA) was scheduled to begin on Monday of the following week (day 0) and to proceed daily until 5À10 Â 10 6 CD34 þ cells/kg (enough for one to two courses of high-dose therapy) were harvested. In general, a peripheral blood (PB) CD34 þ cell count 420/ml was used to move forward with Quinton catheter insertion and/or beginning apheresis. During the study period, an increasing number of patients had apheresis through peripheral veins particularly if they had a high day-0 stem cell count. Apheresis was performed with either the Amicus Separator (Baxter Healthcare, Deerfield, IL, USA) or the Cobe Spectra (Gambro BCT, Lakewood, CO, USA) with an average of 12-18 l processed over approximately 3-4 h on each collection.
Results
Patient and disease characteristics are listed in Table 1 . Patients with renal insufficiency were included although there were no patients on dialysis. Figure 2 shows the efficacy of mobilization with 90 and 68% of patients achieving a peak PB CD34 þ cell count of more than 50 and 100/ml, respectively. Table 2 shows the results of stem cell mobilization and collection. The median yield per apheresis was 4.88 Â 10 6 CD34 þ cells/kg. An institutional minimum stem cell collection (2.5 Â 10 6 CD34 þ cells/kg) was obtained in all 50 patients and in 44 (88%) this was accomplished with the first apheresis. With respect to the predictability of the timing of stem cell mobilization, 43 of 50 patients started collection on day 0 (Monday), one patient was ready on day 0 but was not collected due to the placement of a central catheter, and only one patient required weekend apheresis for poor or delayed mobilization. This patient also received a higher dose of G-CSF. In 34 patients, 45 Â 10 6 CD34 cells were collected in a single apheresis on the planned day 0. In 44 patients, X5 Â 10 6 CD34 þ cells/kg were collected within 2 days and four additional patients required 3-4 days of apheresis to achieve X5 Â 10 6 CD34 þ cells/kg. Finally, although this was not a goal at the time of this study, X10 Â 10 6 CD34 þ cells/kg were collected in 36 of 50 patients, including 33 patients who required only 1-2 days of collection.
The toxicity of the mobilization program was mild. Two patients required admission for fever and neutropenia. Another patient developed a catheter infection. One patient with a history of paroxysmal atrial fibrillation had an episode during apheresis. No patient experienced urothelial toxicity. There was no treatment-related mortality.
Discussion
High-dose chemotherapy with stem cell rescue is the first treatment to improve the survival of patients with multiple myeloma in over 30 years. 1 In contrast to the impact of high-dose therapy on outcome, there is no known advantage for any of the regimens commonly given before Figure 1 Mobilization strategy: apheresis was planned to begin 10 days after cyclophosphamide. Collection was generally started when the PBCD34 count was more than 20/ml. In the latter part of the study period, apheresis was performed via peripheral veins in patients with good venous access. There were a total of 50 patients.
transplant. As a result, the current initial approach in newly diagnosed patients is to offer less stem cell-toxic treatments such as pulse dexamethasone, VAD or thalidomide/ decadron until stem cells have been collected. 3, 4 This approach has made stem cell collection easier and more productive than in patients who have been heavily pretreated with alkylating agent-based regimens. 5, 9 Thus, in the current study of cyclophosphamide of 1.5 g/m 2 and G-CSF of 10 mg/kg, all 50 patients achieved a stem cell collection of 42.5 Â 10 6 CD34 þ cells/kg and the median number of stem cells collected per apheresis was 4.88 Â 10 6 CD34 þ cells/kg. In addition, there was a remarkably predictable pattern of stem cell mobilization and neutrophil recovery with 44 of 50 patients ready for collection on day 0 (Monday), and only two patients required weekend apheresis.
As most patients only required one or two apheresis procedures to collect enough stem cells for tandem transplants, we currently do not insert central catheters in patients with robust mobilization (predicted by the day 0 PBCD34 þ cell count) 10 and adequate peripheral venous access. In fact, although catheters were routinely used at the beginning of the study period, overall 52% of patients did not require a catheter for apheresis. This mobilization regimen was also well tolerated with a 4% incidence of admission for fever and neutropenia. The low toxicity profile is considered particularly important in myeloma patients because of the older age of the population and the inherent immunodeficiency associated with the disease. In contrast, high-dose cyclophosphamide programs require hospitalization for administration and are associated with a high incidence of subsequent admissions for fever and neutropenia as well as more intensive transfusion support. 7, 11 As many other studies of stem cell mobilization in patients with multiple myeloma included patients previously treated with alkylating agents, it is difficult to compare the present results with those achieved using other strategies. In a cohort of patients of whom 73% were alkylating agent naive, Lazzarino and co-workers 11, 12 found that a well-tolerated regimen of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) given by continuous infusion over 4 days followed by 5 mg/kg G-CSF yielded a median of 5.8 Â 10 6 CD34 þ cells/kg after a median of two aphereses. No patient required admission for fever and neutropenia and transfusion support was minimal. The median yield (2.9 vs 4.88 Â 10 6 CD34 þ cells/ kg was slightly lower compared to the present study. However, the need for in-patient hospitalization for the mobilizing chemotherapy represents a significant disadvantage. Finally, patients with compromised renal function were not candidates for the cisplatin-containing regimen.
In a study population similar to our own, Jantunen et al ). The lowdose cyclophosphamide group received G-CSF at a dose of 5-10 mg/kg (median 7 mg/kg), while the intermediate-dose group received G-CSF at a dose of 5 mg/kg. Both groups received cyclophosphamide in the hospital followed by MESNA uroprophylaxis. Mobilization with the low-dose cyclophosphamide regimen was at least as effective as the higher dose program and resulted in higher peak PBCD34 þ counts and consequently higher median stem cell collections per apheresis. Their median yield per collection was similar to that seen in the present study and 88% of patients achieved at least a minimally adequate collection with the first apheresis procedure.
The optimal mobilization regimen for multiple myeloma has not been defined. Ideally, the mobilizing program would provide additional antineoplastic activity and decrease the number of contaminating tumor cells. Mobilizing therapy with high-dose cyclophosphamide provides a modest therapeutic effect after three cycles of VAD with an additional 21% of patients achieving a partial response. 7 These results must be balanced against the morbidity associated with a prolonged period of neutropenia similar to that experienced after high-dose therapy and stem cell rescue.
The available evidence suggests that while myeloma cell contamination of unselected stem cell products is nearly universal, [14] [15] [16] its impact upon relapse appears to be less than the influence of resistant residual disease. Thus, in a randomized trial, rescue with CD34 þ selected cells offered no advantage in terms of time to relapse or overall survival compared to unmanipulated cells despite a dramatic tumor cell reduction in the stem cell product. 17 Nevertheless, tumor cell contamination could become important if a more effective preparative treatment becomes available. Few studies have examined the impact of the stem cell mobilizing strategy on myeloma cell contamination. Knudsen et al 18 found that when apheresis was timed to coincide with a PBCD34 þ cell count greater than 20/ml, there was concomitant tumor cell mobilization coinciding with peak PBCD34 þ cell counts. In seven patients who were mobilized with G-CSF alone and then mobilized a second time with 2.0 g/m 2 cyclophosphamide plus G-CSF, there appeared to be a higher number of myeloma cells mobilized when G-CSF was used alone, although the difference was not statistically significant. In a different study, the combination of cyclophosphamide plus G-CSF mobilized a higher number of CD34 þ cells and a lower number of myeloma cells than with G-CSF alone. 19 A recent investigation incorporating real-time polymerase chain reaction technology does not support the use of repeated intensive therapy as an effective strategy for in vivo purging in patients with multiple myeloma. In five patients mobilized with sequential courses of high-dose cyclophosphamide (5 g/m 2 ), the second stem cell product was not significantly less contaminated than the first and the authors concluded that ex vivo purging offered greater promise as a method of obtaining an uncontaminated stem cell product. 20 These results stand in contrast to those recently achieved in patients with follicular and mantle cell lymphoma where the combination of chemotherapy and rituximab appear quite effective as in vivo purging agents. [21] [22] [23] In view of the relatively modest impact of the mobilizing regimen as a debulking program and the lack of in vivo purging produced by chemotherapy, there has been increased interest in the use of G-CSF alone for mobilizing stem cells in myeloma patients. Mobilization with G-CSF alone is generally well tolerated, avoids unplanned apheresis, can be accomplished over a shorter number of days than chemotherapy and does not necessitate a subsequent rest period like that required after aggressive chemotherapy. 6 In heavily pretreated patients, it has also been suggested that chemotherapy-induced mobilization is more impaired than cytokine mobilization alone. 24, 25 In a recent comparison of patients mobilized with cyclophosphamide plus G-CSF vs G-CSF alone, comparable engraftment kinetics were observed despite a lower number of administered CD34 þ cells in the G-CSF mobilized group. 6 Potential disadvantages of G-CSF mobilization include a greater number of required aphereses (and likely need for a central catheter) and a significantly lower yield of stem cells. In a retrospective study of multiple myeloma patients, the inferiority of G-CSF alone as a mobilizing agent extended to heavily pretreated patients except in those who were thrombocytopenic at the time of mobilization where the advantage of chemotherapy plus G-CSF disappeared. 26 In addition, mobilization with high-dose G-CSF is not completely benign. In the study by Desikan et al, 6 one-third of patients mobilized with G-CSF alone required admission for disease-related complications and catheter thrombosis. The Arkansas group also noted a higher incidence of delayed and incomplete engraftment in patients with more extensive disease who were given a lower number of stem cells. 9, 26 Further, as essentially all patients with myeloma eventually relapse and require additional therapy, further studies are required to assess subsequent chemotherapy tolerance in patients given a lower number of stem cells at transplant. 27 Finally, a recent study showed that overall survival was significantly higher in patients given more than 5 Â 10 6 CD34 þ cells/kg. 28 Although the reason for this finding is unclear, it seems possible that immune reconstitution may be faster and/or more complete in patients given a higher number of stem cells. Porrata et al have shown improved survival after autologous transplant in patients with multiple myeloma and NHL who achieved more rapid lymphocyte recovery. However, they did not find a correlation between rapid lymphocyte recovery and infused CD34 þ cell dose. 29 In summary, an outpatient dose of cyclophosphamide plus G-CSF is a safe, predictable and highly effective method for mobilizing stem cells in patients with newly diagnosed multiple myeloma. The greater mobilizing potential of higher doses of cyclophosphamide is not required in patients who have not received alkylating agents and is associated with more toxicity. Further studies are required that compare cyclophosphamide plus G-CSF vs G-CSF alone in non-heavily pretreated patients. These studies should examine cost effectiveness, ability to mobilize enough stem cells to support tandem transplants, tolerance to subsequent chemotherapy and overall survival.
